Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism

References

• Alouane A, Labruere R, Le Saux T, et al. (2015). Self-immolative spacers: kinetic aspects, structure-property relationships, and applications. Angew Chem Int Ed Engl 54:7492–509.
   PubMed Web of Science ®Google Scholar
• Cao F, Guo JX, Ping QN, Liao ZG. (2006). Prodrugs of scutellarin: ethyl, benzyl and N,N-diethylglycolamide ester synthesis, physicochemical properties, intestinal metabolism and oral bioavailability in the rats. Eur J Pharm Sci 29:385–93.
   PubMed Web of Science ®Google Scholar
• Chen X, Cui L, Duan X, et al. (2006). Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Drug Metab Dispos 34:1345–52.
   PubMed Web of Science ®Google Scholar
• Chledzik S, Strawa J, Matuszek K, Nazaruk J. (2018). Pharmacological effects of scutellarin, an active component of genus scutellaria and erigeron: a systematic review. Am J Chin Med 46:319–37.
   PubMed Web of Science ®Google Scholar
• Dal Corso A, Borlandelli V, Corno C, et al. (2020). Fast cyclization of a proline-derived self-immolative spacer improves the efficacy of carbamate prodrugs. Angew Chem Int Ed Engl 59:4176–81.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhang S, Tu J, et al. (2012). Novel function of scutellarin in inhibiting cell proliferation and inducing cell apoptosis of human Burkitt lymphoma Namalwa cells. Leuk Lymphoma 53:2456–64.
   PubMed Web of Science ®Google Scholar
• Gao C, Chen X, Zhong D. (2011). Absorption and disposition of scutellarin in rats: a pharmacokinetic explanation for the high exposure of its isomeric metabolite. Drug Metab Dispos 39:2034–44.
   PubMed Web of Science ®Google Scholar
• Gao C, Zhang H, Guo Z, et al. (2012). Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos 40:2009–20.
   PubMed Web of Science ®Google Scholar
• Guo LL, Guan ZZ, Huang Y, et al. (2013). The neurotoxicity of β-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scutellarin . Exp Toxicol Pathol 65:579–84.
   PubMed Web of Science ®Google Scholar
• Hu L, Quach T, Han S, et al. (2016). Glyceride-mimetic prodrugs incorporating self-immolative spacers promote lymphatic transport, avoid first-pass metabolism, and enhance oral bioavailability. Angew Chem Int Ed Engl 55:13700–5.
   PubMedGoogle Scholar
• Huang JM, Weng WY, Huang XB, et al. (2005). Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats. Eur J Drug Metab Pharmacokinet 30:165–70.
   PubMed Web of Science ®Google Scholar
• Lu J, Cheng C, Zhao X, et al. (2010). PEG-scutellarin prodrugs: synthesis, water solubility and protective effect on cerebral ischemia/reperfusion injury. Eur J Med Chem 45:1731–8.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li H, Guan S. (2015). Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system. Drug Dev Ind Pharm 41:177–82.
   PubMed Web of Science ®Google Scholar
• Marina Shamis HNL, Shabat D. (2003). Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. JACS 126:1276–731.
   Web of Science ®Google Scholar
• Markovic M, Ben-Shabat S, Aponick A, et al. (2020). Lipids and lipid-processing pathways in drug delivery and therapeutics. Int J Mol Sci 21:3248..
   Web of Science ®Google Scholar
• Mu H, Høy C-E. (2004). The digestion of dietary triacylglycerols. Prog Lipid Res 43:105–33.
   PubMed Web of Science ®Google Scholar
• Peng Dayan GY. (2011). Clinical observation on breviscapine injection on unstable angina pectoris combined with hyperlipidemia. J Hubei Coll Tradit Chinese Med 13:15–7.
   Google Scholar
• Qiu F, Xia H, Zhang T, et al. (2007). Two major urinary metabolites of scutellarin in rats. Planta Med 73:363–5.
   PubMed Web of Science ®Google Scholar
• Ryšánek P, Grus T, Šíma M, Slanař O. (2020). Lymphatic transport of drugs after intestinal absorption: impact of drug formulation and physicochemical properties. Pharm Res 37:166.
   PubMed Web of Science ®Google Scholar
• Tian C, Guo J, Wang G, et al. (2019). Efficient intestinal digestion and on site tumor-bioactivation are the two important determinants for chylomicron-mediated lymph-targeting triglyceride-mimetic docetaxel oral prodrugs. Adv Sci 6:1901810.
   Web of Science ®Google Scholar
• Trevaskis NL, Kaminskas LM, Porter CJ. (2015). From sewer to saviour – targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov 14:781–803.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ao H, Qian Z, Zheng Y. (2011). Intestinal transport of scutellarein and scutellarin and first-pass metabolism by UDP-glucuronosyltransferase-mediated glucuronidation of scutellarein and hydrolysis of scutellarin. Xenobiotica 41:538–48.
   PubMed Web of Science ®Google Scholar
• Wang L, Ma Q. (2018). Clinical benefits and pharmacology of scutellarin: a comprehensive review. Pharmacol Ther 190:105–27.
   PubMed Web of Science ®Google Scholar
• Wang T, Shen L, Zhang Z, et al. (2017). A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption. Drug Deliv 24:1565–73.
   PubMed Web of Science ®Google Scholar
• Wang J, Tan J, Luo J, et al. (2017). Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy. J Nanobiotechnol 15:18.
   PubMed Web of Science ®Google Scholar
• Xing JF, You HS, Dong YL, et al. (2011). Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces. Acta Pharmacol Sin 32:655–63.
   PubMed Web of Science ®Google Scholar
• Yan L, Huang H, Tang QZ, et al. (2010). Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. J Cell Biochem 109:1158–71.
   PubMed Web of Science ®Google Scholar
• Yang X, Miao X, Cao F, et al. (2014). Nanosuspension development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin. J Pharm Sci 103:3576–84.
   PubMed Web of Science ®Google Scholar